La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aytu BioPharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aytu BioPharma..

Aytu BioPharma (NASDAQ:AYTU) Azioni, Catena delle Opzioni

Aytu BioPharma

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Inc

News

PBYI

Puma Biotechnology Presents Clinical Data Of Phase I Trial Of trastuzumab deruxtecan In Combination With Neratinib In Solid Tumors With HER2 Alterations At AACR 2025

<p>The <a href="https://www.benzinga.com/general/sports/25/04/44990571/2025-nfl-draft-how-to-watch-betting-odds-will-record-first-round-happen">2025 NFL Draft</a> is complete, and attention turns to how rookies will factor into their new team's depth charts for the next season.</p>
<p>Here's a look at the early Rookie of the Year betting odds.</p>
<p><strong>Offensive Rookie of the Year: </strong>The quarterback position remains one of the most important in the NFL and last year's 2024 NFL Draft saw <strong>Jayden Daniels</strong> win the offensive rookie of the year after being one of a record-tying six quarterbacks drafted <a href="https://www.benzinga.com/general/sports-betting/24/04/38501129/2024-nfl-draft-recap-quarterbacks-wide-receivers-detroit-set-records-who-will-win-rookie-o">in the first round.</a></p>
<p>In the 2025 NFL Draft, there were only two quarterbacks drafted in the first round. <strong>Cam Ward </strong>is the number one overall pick by the Tennessee Titans. Jaxson Dart was selected later in the first round by the New York Giants.</p>
<p>In the last two seasons, the second overall pick and quarterback selected second in the draft has won the Rookie of the Year. Daniels won last year and<strong> C.J. Stroud </strong>won the year before that.</p>
<p>While Dart went later in the first round, he would fit that current trend of being the second quarterback drafted and the best rookie. Dart isn't expected to start in the 2025 NFL season with <strong>Russell Wilson</strong> brought in to lead the way, but who knows what will happen.</p>
<p>The big storyline in the 2025 NFL Draft was Colorado quarterback <strong>Shedeur Sanders</strong> falling out of the first round and dropping down to the fifth round where he was taken by the Cleveland Browns who now have five quarterbacks competing for the starting role including Sanders and fellow 2025 NFL Draft pick Dillon Gabriel, taken 94<sup>th</sup> overall in the third round.</p>
<p>Sanders will have a chip on his shoulder after falling in the draft, but given the Browns' depth at the position, he may not see the field next season.</p>
<p>Here are the current betting odds for the 2025 Offensive Rookie of the Year from <strong>DraftKings Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>):</p>
<ul>
<li><strong>Ashton Jeanty</strong> (Raiders, RB): +200</li>
<li><strong>Cam Ward</strong> (Titans, QB): +230</li>
<li><strong>Travis Hunter</strong> (Jaguars, WR): +750</li>
<li><strong>Tyler Shough</strong> (Saints, QB): +1,200</li>
<li><strong>Tetairoa McMillan</strong> (Panthers, WR): +1,400</li>
<li><strong>Omarion Hampton</strong> (Chargers, RB): +1,600</li>
<li><strong>Quinshon Judkins</strong> (Browns, RB): +1,800</li>
<li><strong>Shedeur Sanders </strong>(Browns, QB): +1,900</li>
<li><strong>TreVeyon Henderson </strong>(Patriots, RB): +2,000</li>
<li><strong>Colston Loveland</strong> (Bears, TE): +2,200</li>
</ul>
<p>Of the top betting favorites, Shough, Judkins, Sanders and Henderson were all drafted after the first round. Over the last 10 seasons, the offensive rookie of the year has come from the first round eight times, with <strong>Alvin Kamara</strong> (second round) and <strong>Dak Prescott </strong>(fourth round) the exceptions.</p>
<p>Shough could be the immediate starter for the Saints and get a chance to compete for the award.</p>
<p>Another trend to watch will be the tight end position with <strong>Brock Bowers</strong> (Raiders) placing second in voting last year after breaking several records for the position. No tight end has ever won offensive rookie of the year.</p>
<p>Tight ends Loveland and<strong> Tyler Warren </strong>(+3,000) were first round picks who will be likely day one starters and could compete for the award as long as no quarterback has a huge season.</p>
<p>In the last 10 seasons, there have been five quarterbacks to win the award, along with three running backs and two wide receivers.</p>
<p>Travis Hunter is the other topic to watch as he is a two-way player and expected to play both wide receiver and cornerback for the Jaguars, who moved up to take him in the 2025 draft.</p>
<p>Fanduel, owned by <strong>Flutter Entertainment </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), also has betting lines of Hunter winning either rookie of the year award at odds of +440 and odds of him winning both offensive and defensive rookie of the year at +5,000.</p>
<p>With Hunter playing both sides of the ball, it may hurt his chances of winning either award, while playing both positions likely helped him winning the Heisman Trophy, which went to the best overall college football player for both offense and defense.</p>
<p>Across the last 10 drafts, the second overall pick won five Rookie of the Year awards for either offense or defense. That trend that could favor Hunter.</p>
<p>Ahead of the 2024 NFL season, first overall pick QB Caleb Williams (Bears) was the early favorite, while Daniels was listed with odds of +650.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/general/sports/24/12/42521231/travis-hunter-wins-heisman-will-he-be-1-pick-in-2025-nfl-draft-what-betting-odds-history-show">Travis Hunter Wins Heisman, Will He Be #1 Pick In 2025 NFL Draft? What Betting Odds, History Show</a></strong></p>
<p><strong>Defensive Rookie of the Year</strong>: On the other side of the ball, the defensive rookie of the year has been dominant by players taken in the first round.</p>
<p>Of the last 10 NFL Drafts, nine of the defensive rookie of the years came from the first round with the 19<sup>th</sup> pick or earlier. The one exception was a player taken 36<sup>th</sup> overall in the second round.</p>
<p>The defensive rookie of the year has been fairly evenly split by position with three linebackers winning, three defensive ends winning, three cornerbacks winning and one defensive lineman winning.</p>
<p>Here are the betting favorites for defensive rookie of the year at DraftKings:</p>
<ul>
<li><strong>Abdul Carter</strong> (Giants, Edge/DE): +250</li>
<li><strong>Travis Hunter</strong> (Jaguars, CB): +750</li>
<li><strong>Mykel Williams </strong>(49ers, Edge/DE): +900</li>
<li><strong>Jalon Walker</strong> (Falcons, LB): +900</li>
<li><strong>Jihaad Campbell</strong> (Eagles, LB): +1,200</li>
<li><strong>Mason Graham</strong> (Browns, DT): +1,400</li>
<li><strong>Shemar Stewart</strong> (Bengals, Edge/DE): +1,600</li>
<li><strong>Mike Green</strong> (Ravens, Edge/DE)): +1,600</li>
</ul>
<p>All the favorites were first round picks, outside of Green, who slid to the second round.</p>
<p>Last year, <strong>Jared Verse </strong>started the season ranked fourth at +1,100 odds after the NFL Draft before going on to win the defensive rookie of the year. Cater, who was considered the top prospect in the draft by some experts, is likely to stay the defensive favorite until the season begins.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43608426/super-bowl-lix-rematch-again-sportsbooks-list-eagles-chiefs-as-top-favorites-for-super-bowl-lx">Super Bowl LIX Rematch Again? Sportsbooks List Eagles, Chiefs As Top Favorites For Super Bowl LX</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Sports Betting

Sports

DKNG

FLUT

NFL Rookie Of The Year Betting Odds: Shedeur Sanders Payout, Travis Hunter To Win Both Awards?

<p>JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect JetBlue Airways to report an <strong>earnings per share</strong> (EPS) of $-0.62.</p>
<p>Investors in JetBlue Airways are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 1.5% increase in the share price the following trading session.</p>
<p>Here's a look at JetBlue Airways's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.30</td>
<td>-0.25</td>
<td>-0.11</td>
<td>-0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>-0.16</td>
<td>0.08</td>
<td>-0.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866977_0.png" alt="eps graph" /></p>
<h3>Market Performance of JetBlue Airways's Stock</h3>
<p>Shares of JetBlue Airways were trading at $3.88 as of April 25. Over the last 52-week period, shares are down 28.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on JetBlue Airways</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on JetBlue Airways.</p>
<p>Analysts have provided JetBlue Airways with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $4.44, suggesting a potential 14.43% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Allegiant Travel, Frontier Group Holdings and Sun Country Airlines, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Allegiant Travel, with an average 1-year price target of $64.43, suggesting a potential 1560.57% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Frontier Group Holdings, with an average 1-year price target of $7.02, suggesting a potential 80.93% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sun Country Airlines, with an average 1-year price target of $14.5, suggesting a potential 273.71% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Allegiant Travel, Frontier Group Holdings and Sun Country Airlines, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>JetBlue Airways</td>
<td>Neutral</td>
<td>-2.06%</td>
<td>$426M</td>
<td>-1.67%</td>
</tr>
<tr>
<td>Allegiant Travel</td>
<td>Neutral</td>
<td>2.73%</td>
<td>$115.95M</td>
<td>-18.10%</td>
</tr>
<tr>
<td>Frontier Group Holdings</td>
<td>Neutral</td>
<td>12.46%</td>
<td>$83M</td>
<td>9.19%</td>
</tr>
<tr>
<td>Sun Country Airlines</td>
<td>Neutral</td>
<td>6.05%</td>
<td>$58.63M</td>
<td>2.39%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>JetBlue Airways ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.</p>
<h3>About JetBlue Airways</h3>
<p>JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic &amp; Canada segment.</p>
<h3>JetBlue Airways's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Challenges:</strong> JetBlue Airways's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-2.06%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> JetBlue Airways's net margin excels beyond industry benchmarks, reaching <strong>-1.93%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> JetBlue Airways's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-1.67%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> JetBlue Airways's ROA excels beyond industry benchmarks, reaching <strong>-0.26%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> JetBlue Airways's debt-to-equity ratio surpasses industry norms, standing at <strong>3.46</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/JBLU/earnings"><strong>To track all earnings releases for JetBlue Airways visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

JBLU

JetBlue Airways's Earnings Outlook

<p>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Sage Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.99.</p>
<p>The market awaits Sage Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.20 in the last quarter, leading to a 0.42% drop in the share price on the following day.</p>
<p>Here's a look at Sage Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.36</td>
<td>-1.53</td>
<td>-1.66</td>
<td>-1.65</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.56</td>
<td>-1.53</td>
<td>-1.70</td>
<td>-1.80</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>-24.0%</td>
<td>-11.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866969_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Sage Therapeutics were trading at $7.79 as of April 25. Over the last 52-week period, shares are down 44.51%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Perspectives on Sage Therapeutics</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sage Therapeutics.</p>
<p>A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Regenxbio, Precigen and MeiraGTx Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Regenxbio, with an average 1-year price target of $32.0, suggesting a potential 310.78% upside.</li>
<li>Analysts currently favor an Buy trajectory for Precigen, with an average 1-year price target of $6.0, suggesting a potential 22.98% downside.</li>
<li>Analysts currently favor an Buy trajectory for MeiraGTx Hldgs, with an average 1-year price target of $24.5, suggesting a potential 214.51% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>Within the peer analysis summary, vital metrics for Regenxbio, Precigen and MeiraGTx Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>-83.56%</td>
<td>$11.33M</td>
<td>-18.84%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sage Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. However, it ranks at the top for Return on Equity, showing a positive trend. Overall, Sage Therapeutics is positioned in the middle compared to its peers based on the provided metrics.</p>
<h3>Delving into Sage Therapeutics's Background</h3>
<p>Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.</p>
<h3>Sage Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Sage Therapeutics faced challenges, resulting in a decline of approximately <strong>-83.56%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Sage Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-747.33%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-18.84%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Sage Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-16.38%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Sage Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/SAGE/earnings"><strong>To track all earnings releases for Sage Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SAGE

What to Expect from Sage Therapeutics's Earnings

<p>ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that ArcBest will report an <strong>earnings per share</strong> (EPS) of $0.52.</p>
<p>The market awaits ArcBest's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.28, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at ArcBest's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.05</td>
<td>1.83</td>
<td>2.08</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.33</td>
<td>1.64</td>
<td>1.98</td>
<td>1.34</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866960_0.png" alt="eps graph" /></p>
<h3>Performance of ArcBest Shares</h3>
<p>Shares of ArcBest were trading at $58.42 as of April 25. Over the last 52-week period, shares are down 47.33%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on ArcBest</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding ArcBest.</p>
<p>With 13 analyst ratings, ArcBest has a consensus rating of Neutral. The average one-year price target is $95.54, indicating a potential 63.54% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Marten Transport, Werner Enterprises and Heartland Express, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Marten Transport, with an average 1-year price target of $19.0, suggesting a potential 67.48% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Werner Enterprises, with an average 1-year price target of $31.0, suggesting a potential 46.94% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Heartland Express, with an average 1-year price target of $9.0, suggesting a potential 84.59% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Marten Transport, Werner Enterprises and Heartland Express, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ArcBest</td>
<td>Neutral</td>
<td>-8.07%</td>
<td>$82.75M</td>
<td>2.22%</td>
</tr>
<tr>
<td>Marten Transport</td>
<td>Outperform</td>
<td>-3.16%</td>
<td>$33.34M</td>
<td>0.56%</td>
</tr>
<tr>
<td>Werner Enterprises</td>
<td>Neutral</td>
<td>-8.18%</td>
<td>$90.90M</td>
<td>0.82%</td>
</tr>
<tr>
<td>Heartland Express</td>
<td>Underperform</td>
<td>-11.90%</td>
<td>$27.38M</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>ArcBest ranks in the middle for revenue growth among its peers. It ranks at the top for gross profit. It ranks in the middle for return on equity.</p>
<h3>All You Need to Know About ArcBest</h3>
<p>ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.</p>
<h3>Understanding the Numbers: ArcBest's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, ArcBest faced challenges, resulting in a decline of approximately <strong>-8.07%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> ArcBest's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.9%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> ArcBest's ROE excels beyond industry benchmarks, reaching <strong>2.22%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> ArcBest's ROA excels beyond industry benchmarks, reaching <strong>1.2%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> ArcBest's debt-to-equity ratio is below the industry average at <strong>0.31</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/ARCB/earnings"><strong>To track all earnings releases for ArcBest visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ARCB

Uncovering Potential: ArcBest's Earnings Preview

<p>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect NeoGenomics to report an <strong>earnings per share</strong> (EPS) of $-0.01.</p>
<p>The market awaits NeoGenomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 2.54% increase in the share price on the following day.</p>
<p>Here's a look at NeoGenomics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.04</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>4.0%</td>
<td>18.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866952_0.png" alt="eps graph" /></p>
<h3>Market Performance of NeoGenomics's Stock</h3>
<p>Shares of NeoGenomics were trading at $10.27 as of April 25. Over the last 52-week period, shares are down 29.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Observations about NeoGenomics</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding NeoGenomics.</p>
<p>The consensus rating for NeoGenomics is Buy, derived from 5 analyst ratings. An average one-year price target of $17.0 implies a potential 65.53% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Astrana Health, OPKO Health and Pediatrix Medical Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Astrana Health, with an average 1-year price target of $47.4, suggesting a potential 361.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for OPKO Health, with an average 1-year price target of $2.75, suggesting a potential 73.22% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Pediatrix Medical Group, with an average 1-year price target of $17.5, suggesting a potential 70.4% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Astrana Health, OPKO Health and Pediatrix Medical Group, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>Buy</td>
<td>10.57%</td>
<td>$77.26M</td>
<td>-1.69%</td>
</tr>
<tr>
<td>Astrana Health</td>
<td>Buy</td>
<td>88.43%</td>
<td>$50.48M</td>
<td>-0.98%</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>Buy</td>
<td>0.95%</td>
<td>$84.66M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Pediatrix Medical Group</td>
<td>Neutral</td>
<td>1.19%</td>
<td>$128.53M</td>
<td>4.07%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>NeoGenomics ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, NeoGenomics is at the bottom.</p>
<h3>About NeoGenomics</h3>
<p>NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.</p>
<h3>A Deep Dive into NeoGenomics's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining NeoGenomics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>10.57%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-8.91%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-1.69%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> NeoGenomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.93%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.67</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/NEO/earnings"><strong>To track all earnings releases for NeoGenomics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: NeoGenomics's Quarterly Earnings

<p><strong>AtriCure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that AtriCure will report an <strong>earnings per share</strong> (EPS) of $-0.22. </p>
<p>The announcement from AtriCure is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.07, leading to a 6.54% drop in the share price on the subsequent day.</p>
<p>Here's a look at AtriCure's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.15</td>
<td>-0.19</td>
<td>-0.17</td>
<td>-0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.17</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>18.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866944_0.png" alt="eps graph" /></p>
<h3>Market Performance of AtriCure's Stock</h3>
<p>Shares of AtriCure were trading at $33.4 as of April 25. Over the last 52-week period, shares are up 39.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Views on AtriCure</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on AtriCure.</p>
<p>Analysts have provided AtriCure with 13 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $53.15, suggesting a potential 59.13% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Conmed, Omnicell and QuidelOrtho, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Conmed, with an average 1-year price target of $72.2, suggesting a potential 116.17% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Omnicell, with an average 1-year price target of $45.33, suggesting a potential 35.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for QuidelOrtho, with an average 1-year price target of $43.67, suggesting a potential 30.75% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Conmed, Omnicell and QuidelOrtho, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AtriCure</td>
<td>Outperform</td>
<td>16.64%</td>
<td>$92.62M</td>
<td>-3.36%</td>
</tr>
<tr>
<td>Conmed</td>
<td>Neutral</td>
<td>5.78%</td>
<td>$198.34M</td>
<td>3.56%</td>
</tr>
<tr>
<td>Omnicell</td>
<td>Neutral</td>
<td>18.56%</td>
<td>$141.76M</td>
<td>1.28%</td>
</tr>
<tr>
<td>QuidelOrtho</td>
<td>Neutral</td>
<td>-4.69%</td>
<td>$326.10M</td>
<td>-5.78%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>AtriCure ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, AtriCure's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its shareholders.</p>
<h3>About AtriCure</h3>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.</p>
<h3>AtriCure: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining AtriCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.64%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> AtriCure's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-12.53%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-3.36%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> AtriCure's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-2.54%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> AtriCure's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/earnings"><strong>To track all earnings releases for AtriCure visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ATRC

AtriCure Earnings Preview

<p>Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Silicon Motion Technology to report an <strong>earnings per share</strong> (EPS) of $0.45.</p>
<p>Anticipation surrounds Silicon Motion Technology's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.07, leading to a 1.85% drop in the share price on the subsequent day.</p>
<p>Here's a look at Silicon Motion Technology's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.84</td>
<td>0.85</td>
<td>0.94</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.92</td>
<td>0.96</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-4.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866935_0.png" alt="eps graph" /></p>
<h3>Market Performance of Silicon Motion Technology's Stock</h3>
<p>Shares of Silicon Motion Technology were trading at $45.11 as of April 25. Over the last 52-week period, shares are down 40.39%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SIMO/earnings"><strong>To track all earnings releases for Silicon Motion Technology visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SIMO

Silicon Motion Technology's Earnings Outlook

<p>Hillenbrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Hillenbrand to report an <strong>earnings per share</strong> (EPS) of $0.54.</p>
<p>Hillenbrand bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 7.3% drop in the share price the next day.</p>
<p>Here's a look at Hillenbrand's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.92</td>
<td>0.82</td>
<td>0.75</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.56</td>
<td>1.01</td>
<td>0.85</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>12.0%</td>
<td>-4.0%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866927_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Hillenbrand were trading at $22.52 as of April 25. Over the last 52-week period, shares are down 53.23%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HI/earnings"><strong>To track all earnings releases for Hillenbrand visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Hillenbrand's Earnings Potential

<p>Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Ribbon Comms to report an <strong>earnings per share</strong> (EPS) of $0.00.</p>
<p>Ribbon Comms bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.04, leading to a 15.47% increase in the share price the following trading session.</p>
<p>Here's a look at Ribbon Comms's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>0.06</td>
<td>0.05</td>
<td>0</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.16</td>
<td>0.05</td>
<td>0.05</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>15.0%</td>
<td>8.0%</td>
<td>-17.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866918_0.png" alt="eps graph" /></p>
<h3>Tracking Ribbon Comms's Stock Performance</h3>
<p>Shares of Ribbon Comms were trading at $3.61 as of April 25. Over the last 52-week period, shares are up 16.09%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Ribbon Comms</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ribbon Comms.</p>
<p>With 1 analyst ratings, Ribbon Comms has a consensus rating of Outperform. The average one-year price target is $6.0, indicating a potential 66.2% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Adtran Holdings, Applied Optoelectronics and Netgear, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Adtran Holdings, with an average 1-year price target of $13.33, suggesting a potential 269.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for Applied Optoelectronics, with an average 1-year price target of $33.2, suggesting a potential 819.67% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Netgear, with an average 1-year price target of $29.0, suggesting a potential 703.32% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>Within the peer analysis summary, vital metrics for Adtran Holdings, Applied Optoelectronics and Netgear are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ribbon Comms</td>
<td>Outperform</td>
<td>11.02%</td>
<td>$140.07M</td>
<td>1.59%</td>
</tr>
<tr>
<td>Adtran Holdings</td>
<td>Buy</td>
<td>7.70%</td>
<td>$91.23M</td>
<td>-24.65%</td>
</tr>
<tr>
<td>Applied Optoelectronics</td>
<td>Buy</td>
<td>65.87%</td>
<td>$28.73M</td>
<td>-54.26%</td>
</tr>
<tr>
<td>Netgear</td>
<td>Outperform</td>
<td>-3.32%</td>
<td>$59.38M</td>
<td>-1.63%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ribbon Comms ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<h3>Discovering Ribbon Comms: A Closer Look</h3>
<p>Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.</p>
<h3>A Deep Dive into Ribbon Comms's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ribbon Comms showcased positive performance, achieving a revenue growth rate of <strong>11.02%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Ribbon Comms's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.53%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ribbon Comms's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.59%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ribbon Comms's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.56%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.95</strong>, Ribbon Comms adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/RBBN/earnings"><strong>To track all earnings releases for Ribbon Comms visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RBBN

A Glimpse of Ribbon Comms's Earnings Potential

<p><strong>Pony AI Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares are running Monday following reports that the Chinese robotaxi company has accelerated its<a href="https://www.benzinga.com/25/04/45041206/cemex-posts-q1-results-joins-plug-power-sabre-and-other-big-stocks-moving-higher-on-monday"> timeline to profitability</a>.</p>
<p><strong>What To Know:</strong> Pony AI chief technology officer <strong>Lou Tiancheng</strong> told <a href="https://www.wsj.com/business/chinese-robotaxi-firm-pony-ai-on-faster-track-to-profit-after-cost-cuts-cto-says-64977cba">The Wall Street Journal</a> that the company is getting closer to becoming profitable following a series of cost-cutting measures. </p>
<p>Following the release of three new robotaxis at the Shanghai Auto Show last week,&nbsp;company executives reportedly said Pony AI can build its most advanced autonomous driving systems for 70% less than before.</p>
<p>Analysts estimated that the robotaxi company has lowered its bill-of-materials costs for its robotaxis from approximately $137,000 to approximately $41,000. Analysts further estimated that Pony AI could be able to reach single-unit breakeven goals by the end of 2025.</p>
<p>The Pony AI technology chief said in the interview with The Wall Street Journal that the company has been able to cut costs through software optimization, adding that Pony AI tripled performance using the same level of computing power. </p>
<p>The report indicates that Pony AI is planning to start mass producing its robotaxis by mid-2025 and is targeting adding an additional 700 vehicles to its fleet by the end of the year. </p>
<p>Pony AI was publicly listed on the Nasdaq in late 2024. The company reported a loss of 31 cents per share for the fourth quarter, down from a loss of 20 cents per share in the prior year&#8217;s quarter. Sales for the period totaled $35.52 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>Check This Out: <a href="https://www.benzinga.com/25/04/45029177/trumps-autonomous-vehicles-stance-bezos-vs-tesla-and-more-this-week-in-mobility">Trump&#8217;s Autonomous Vehicles Stance, Bezos Vs. Tesla, And More: This Week In Mobility</a></strong></p>
<h3 class="wp-block-heading">Is PONY A Good Stock To Buy?</h3>
<p>An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages  &#8211; like <a href="https://www.benzinga.com/quote/PONY">Pony AI</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.</p>
<p>These are known as capital allocation programs. Pony AI does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.</p>
<p>Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/PONY">Pony AI</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.</p>
<p><strong>PONY Price Action: </strong><a href="http://benzinga.com/quote/PONY">Pony AI shares</a> were up 47.7% Monday afternoon, trading at $10.36 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: <a href="https://www.shutterstock.com/g/tadaimages">Tada Images</a>/Shutterstock.</em></p>


Global

Movers

PONY

Pony AI Stock Is Galloping Higher Monday: Here's What Investors Are Watching

<p><a href="https://www.theverge.com/news/657336/whatsapp-voice-video-call-buttons-web-client" title="https://www.theverge.com/news/657336/whatsapp-voice-video-call-buttons-web-client">https://www.theverge.com/news/657336/whatsapp-voice-video-call-buttons-web-client</a></p>


"WhatsApp Is Working On Video And Voice Calls On The Web; ﻿Call Buttons Were Discovered In The Web Client" - The Verge

<p>LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate LendingClub to report an <strong>earnings per share</strong> (EPS) of $0.11.</p>
<p>The market awaits LendingClub's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 14.32% drop in the share price the following trading session.</p>
<p>Here's a look at LendingClub's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.09</td>
<td>0.07</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.08</td>
<td>0.13</td>
<td>0.13</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-14.000000000000002%</td>
<td>11.0%</td>
<td>12.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866910_0.png" alt="eps graph" /></p>
<h3>LendingClub Share Price Analysis</h3>
<p>Shares of LendingClub were trading at $10.96 as of April 25. Over the last 52-week period, shares are up 43.62%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on LendingClub</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on LendingClub.</p>
<p>With 3 analyst ratings, LendingClub has a consensus rating of Outperform. The average one-year price target is $16.33, indicating a potential 49.0% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and Dave, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for  and Dave, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dave</td>
<td>Buy</td>
<td>37.91%</td>
<td>$94.56M</td>
<td>9.92%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>LendingClub ranks at the bottom for Revenue Growth among its peers, with a growth rate of 37.91%. In terms of Gross Profit, LendingClub is also at the bottom with $94.56M. However, LendingClub is in the middle for Return on Equity, standing at 9.92%.</p>
<h3>Discovering LendingClub: A Closer Look</h3>
<p>LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.</p>
<h3>A Deep Dive into LendingClub's Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining LendingClub's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>17.02%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> LendingClub's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>4.48%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> LendingClub's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.72%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> LendingClub's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.09%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<p><a href="https://www.benzinga.com/quote/LC/earnings"><strong>To track all earnings releases for LendingClub visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of LendingClub's Earnings

<p>BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that BridgeBio Pharma will report an <strong>earnings per share</strong> (EPS) of $-0.86.</p>
<p>Investors in BridgeBio Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.31, which was followed by a 0.12% increase in the share price the next day.</p>
<p>Here's a look at BridgeBio Pharma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.09</td>
<td>-0.98</td>
<td>-1.04</td>
<td>-0.89</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.40</td>
<td>-0.86</td>
<td>-1.06</td>
<td>-0.20</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866897_0.png" alt="eps graph" /></p>
<h3>BridgeBio Pharma Share Price Analysis</h3>
<p>Shares of BridgeBio Pharma were trading at $36.305 as of April 25. Over the last 52-week period, shares are up 37.82%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BBIO/earnings"><strong>To track all earnings releases for BridgeBio Pharma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BBIO

A Look Ahead: BridgeBio Pharma's Earnings Forecast

<p><strong>Enova International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Enova International will report an <strong>earnings per share</strong> (EPS) of $2.40. </p>
<p>Enova International bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.34, leading to a 1.59% increase in the share price the following trading session.</p>
<p>Here's a look at Enova International's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.27</td>
<td>2.31</td>
<td>2.07</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.61</td>
<td>2.45</td>
<td>2.21</td>
<td>1.91</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866887_0.png" alt="eps graph" /></p>
<h3>Market Performance of Enova International's Stock</h3>
<p>Shares of Enova International were trading at $97.88 as of April 25. Over the last 52-week period, shares are up 62.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Enova International</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Enova International.</p>
<p>The consensus rating for Enova International is Buy, based on 4 analyst ratings. With an average one-year price target of $134.5, there's a potential 37.41% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of  and Enova International, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Enova International, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enova International</td>
<td>Buy</td>
<td>25.01%</td>
<td>$336.05M</td>
<td>5.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Enova International ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.</p>
<h3>All You Need to Know About Enova International</h3>
<p>Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.</p>
<h3>Enova International: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Enova International showcased positive performance, achieving a revenue growth rate of <strong>25.01%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Enova International's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>8.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Enova International's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.36%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Enova International's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.24%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>3.0</strong>, Enova International faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/ENVA/earnings"><strong>To track all earnings releases for Enova International visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ENVA

Insights into Enova International's Upcoming Earnings

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Airbnb</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABNB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Airbnb.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 56% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $648,423, and 7 are calls, for a total amount of $355,135.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $200.0 for Airbnb, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Airbnb options trades today is 439.3 with a total volume of 1,838.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Airbnb's big money trades within a strike price range of $100.0 to $200.0 over the last 30 days.</p>
<h3>Airbnb Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866882_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$10.1</td>
<td>$9.75</td>
<td>$9.75</td>
<td>$130.00</td>
<td>$117.0K</td>
<td>1.0K</td>
<td align="right">403</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$9.85</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$130.00</td>
<td>$112.8K</td>
<td>1.0K</td>
<td align="right">243</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$9.6</td>
<td>$9.3</td>
<td>$9.3</td>
<td>$130.00</td>
<td>$111.6K</td>
<td>1.0K</td>
<td align="right">123</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.85</td>
<td>$8.6</td>
<td>$8.9</td>
<td>$150.00</td>
<td>$97.8K</td>
<td>1.2K</td>
<td align="right">119</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$10.05</td>
<td>$9.8</td>
<td>$9.8</td>
<td>$130.00</td>
<td>$74.4K</td>
<td>1.0K</td>
<td align="right">403</td>
</tr>
</tbody>
</table>
</p>
<h3>About Airbnb</h3>
<p>Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency; it also offers booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of Dec. 31, 2024. Listings from the company's 5 million-plus hosts are spread over almost every country in the world. In 2024, 45% of revenue was from North America, 37% from Europe, the Middle East, and Africa, 9% from Latin America, and 9% from Asia-Pacific. Transaction fees for online bookings account for all its revenue.</p>
<p>In light of the recent options history for Airbnb, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Airbnb Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,536,740, the ABNB's price is up by 0.33%, now at $122.92. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 3 days.</li>
</ul>
<h3>What Analysts Are Saying About Airbnb</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $131.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Airbnb, which currently sits at a price target of $115.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Neutral rating on Airbnb, which currently sits at a price target of $132.<br />
&#x2A; An analyst from Wells Fargo persists with their Underweight rating on Airbnb, maintaining a target price of $100.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Airbnb, targeting a price of $180.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Underweight rating for Airbnb, targeting a price of $130. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Airbnb, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

ABNB

Airbnb's Options: A Look at What the Big Money is Thinking

<p>DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) underwent analysis by 30 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">12</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $218.33, a high estimate of $245.00, and a low estimate of $175.00. Surpassing the previous average price target of $195.97, the current average has increased by 11.41%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866881_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of DoorDash by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;     Rating      &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Andrew Boone        &#x7C;JMP Securities      &#x7C;Maintains      &#x7C;Market Outperform&#x7C;             $225.00&#x7C;$225.00             &#x7C;<br />
&#x7C;Brian Nowak         &#x7C;Morgan Stanley      &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $210.00&#x7C;$245.00             &#x7C;<br />
&#x7C;Deepak Mathivanan   &#x7C;Cantor Fitzgerald   &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $210.00&#x7C;$230.00             &#x7C;<br />
&#x7C;Justin Patterson    &#x7C;Keybanc             &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $230.00&#x7C;$240.00             &#x7C;<br />
&#x7C;Doug Anmuth         &#x7C;JP Morgan           &#x7C;Lowers         &#x7C;Neutral          &#x7C;             $175.00&#x7C;$205.00             &#x7C;<br />
&#x7C;Michael McGovern    &#x7C;B of A Securities   &#x7C;Lowers         &#x7C;Buy              &#x7C;             $235.00&#x7C;$245.00             &#x7C;<br />
&#x7C;Ken Gawrelski       &#x7C;Wells Fargo         &#x7C;Raises         &#x7C;Equal-Weight     &#x7C;             $201.00&#x7C;$198.00             &#x7C;<br />
&#x7C;Rob Sanderson       &#x7C;Loop Capital        &#x7C;Raises         &#x7C;Buy              &#x7C;             $235.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Shyam Patil         &#x7C;Susquehanna         &#x7C;Raises         &#x7C;Positive         &#x7C;             $235.00&#x7C;$180.00             &#x7C;<br />
&#x7C;Ross Sandler        &#x7C;Barclays            &#x7C;Raises         &#x7C;Equal-Weight     &#x7C;             $200.00&#x7C;$163.00             &#x7C;<br />
&#x7C;Michael McGovern    &#x7C;B of A Securities   &#x7C;Raises         &#x7C;Buy              &#x7C;             $245.00&#x7C;$205.00             &#x7C;<br />
&#x7C;Youssef Squali      &#x7C;Truist Securities   &#x7C;Raises         &#x7C;Buy              &#x7C;             $235.00&#x7C;$217.00             &#x7C;<br />
&#x7C;Lloyd Walmsley      &#x7C;UBS                 &#x7C;Raises         &#x7C;Neutral          &#x7C;             $204.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Jason Helfstein     &#x7C;Oppenheimer         &#x7C;Raises         &#x7C;Outperform       &#x7C;             $235.00&#x7C;$180.00             &#x7C;<br />
&#x7C;Brad Erickson       &#x7C;RBC Capital         &#x7C;Raises         &#x7C;Outperform       &#x7C;             $230.00&#x7C;$215.00             &#x7C;<br />
&#x7C;Eric Sheridan       &#x7C;Goldman Sachs       &#x7C;Raises         &#x7C;Neutral          &#x7C;             $212.00&#x7C;$192.00             &#x7C;<br />
&#x7C;Rohit Kulkarni      &#x7C;Roth MKM            &#x7C;Raises         &#x7C;Neutral          &#x7C;             $193.00&#x7C;$165.00             &#x7C;<br />
&#x7C;Scott Devitt        &#x7C;Wedbush             &#x7C;Raises         &#x7C;Neutral          &#x7C;             $210.00&#x7C;$160.00             &#x7C;<br />
&#x7C;Ken Gawrelski       &#x7C;Wells Fargo         &#x7C;Raises         &#x7C;Equal-Weight     &#x7C;             $198.00&#x7C;$166.00             &#x7C;<br />
&#x7C;Brian Pitz          &#x7C;BMO Capital         &#x7C;Raises         &#x7C;Outperform       &#x7C;             $240.00&#x7C;$180.00             &#x7C;<br />
&#x7C;Doug Anmuth         &#x7C;JP Morgan           &#x7C;Raises         &#x7C;Neutral          &#x7C;             $205.00&#x7C;$155.00             &#x7C;<br />
&#x7C;Thomas Champion     &#x7C;Piper Sandler       &#x7C;Raises         &#x7C;Neutral          &#x7C;             $210.00&#x7C;$160.00             &#x7C;<br />
&#x7C;Deepak Mathivanan   &#x7C;Cantor Fitzgerald   &#x7C;Raises         &#x7C;Overweight       &#x7C;             $230.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Mark Mahaney        &#x7C;Evercore ISI Group  &#x7C;Raises         &#x7C;Outperform       &#x7C;             $240.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Ronald Josey        &#x7C;Citigroup           &#x7C;Raises         &#x7C;Buy              &#x7C;             $240.00&#x7C;$211.00             &#x7C;<br />
&#x7C;James Lee           &#x7C;Mizuho              &#x7C;Raises         &#x7C;Outperform       &#x7C;             $222.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Bernie McTernan     &#x7C;Needham             &#x7C;Raises         &#x7C;Buy              &#x7C;             $225.00&#x7C;$180.00             &#x7C;<br />
&#x7C;Mark Zgutowicz      &#x7C;Benchmark           &#x7C;Raises         &#x7C;Buy              &#x7C;             $220.00&#x7C;$180.00             &#x7C;<br />
&#x7C;Andrew Boone        &#x7C;JMP Securities      &#x7C;Maintains      &#x7C;Market Outperform&#x7C;             $200.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Lloyd Walmsley      &#x7C;UBS                 &#x7C;Raises         &#x7C;Neutral          &#x7C;             $200.00&#x7C;$182.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DoorDash. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DoorDash compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DoorDash's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DASH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on DoorDash analyst ratings.</strong></a></p>
<h2>Get to Know DoorDash Better</h2>
<p>Founded in 2013 and headquartered in San Francisco, DoorDash is an online delivery demand aggregator. Consumers can use its app to order food items on-demand for delivery or in-store from merchants. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe and Asia. DoorDash creates a marketplace for merchants to establish a presence online, market their offerings, and meet demand through delivery. The firm provides similar service to nonrestaurant businesses, such as grocery, retail, and pet supplies. Dash is also rolling out nascent technology like drone delivery in an effort to continually innovate and provide the best possible service to supply-side and demand-side contingents of its marketplace.</p>
<h3>DoorDash's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> DoorDash's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>24.75%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> DoorDash's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.91%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> DoorDash's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.83%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> DoorDash's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.07</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

DASH

Deep Dive Into DoorDash Stock: Analyst Perspectives (30 Ratings)

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>AbbVie</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 27 uncommon options trades for AbbVie.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $433,724, and 18 are calls, for a total amount of $1,629,157.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $220.0 for AbbVie over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $155.0 to $220.0, over the past month.</p>
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866876_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$9.95</td>
<td>$8.85</td>
<td>$9.9</td>
<td>$180.00</td>
<td>$495.0K</td>
<td>897</td>
<td align="right">521</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$15.85</td>
<td>$15.45</td>
<td>$15.65</td>
<td>$185.00</td>
<td>$352.1K</td>
<td>3.6K</td>
<td align="right">291</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$10.5</td>
<td>$10.3</td>
<td>$10.5</td>
<td>$195.00</td>
<td>$95.5K</td>
<td>1.2K</td>
<td align="right">564</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$3.7</td>
<td>$3.55</td>
<td>$3.62</td>
<td>$220.00</td>
<td>$81.4K</td>
<td>1.2K</td>
<td align="right">301</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.65</td>
<td>$8.4</td>
<td>$8.49</td>
<td>$190.00</td>
<td>$80.6K</td>
<td>3.3K</td>
<td align="right">136</td>
</tr>
</tbody>
</table>
</p>
<h3>About AbbVie</h3>
<p>AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).</p>
<p>Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>With a trading volume of 5,816,954, the price of ABBV is up by 3.02%, reaching $191.67.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>Expert Opinions on AbbVie</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $214.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Goldman Sachs downgraded its action to Neutral with a price target of $194.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $210.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on AbbVie, maintaining a target price of $205.<br />
&#x2A; An analyst from Guggenheim has revised its rating downward to Buy, adjusting the price target to $214.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on AbbVie, maintaining a target price of $250. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


ABBV

AbbVie's Options Frenzy: What You Need to Know

<p>23 analysts have shared their evaluations of Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">12</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Carvana and provided 12-month price targets. The average target is $283.91, accompanied by a high estimate of $365.00 and a low estimate of $200.00. This upward trend is evident, with the current average reflecting a 0.24% increase from the previous average price target of $283.22.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866871_0_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Carvana is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;     Rating      &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;David Lantz         &#x7C;Wells Fargo         &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $290.00&#x7C;$310.00             &#x7C;<br />
&#x7C;Alexander Potter    &#x7C;Piper Sandler       &#x7C;Raises         &#x7C;Overweight       &#x7C;             $230.00&#x7C;$225.00             &#x7C;<br />
&#x7C;Nicholas Jones      &#x7C;JMP Securities      &#x7C;Lowers         &#x7C;Market Outperform&#x7C;             $275.00&#x7C;$340.00             &#x7C;<br />
&#x7C;Ronald Josey        &#x7C;Citigroup           &#x7C;Lowers         &#x7C;Buy              &#x7C;             $280.00&#x7C;$320.00             &#x7C;<br />
&#x7C;Colin Sebastian     &#x7C;Baird               &#x7C;Lowers         &#x7C;Neutral          &#x7C;             $200.00&#x7C;$250.00             &#x7C;<br />
&#x7C;Rajat Gupta         &#x7C;JP Morgan           &#x7C;Lowers         &#x7C;Overweight       &#x7C;             $325.00&#x7C;$365.00             &#x7C;<br />
&#x7C;Adam Jonas          &#x7C;Morgan Stanley      &#x7C;Raises         &#x7C;Overweight       &#x7C;             $280.00&#x7C;$260.00             &#x7C;<br />
&#x7C;Alexander Potter    &#x7C;Piper Sandler       &#x7C;Maintains      &#x7C;Overweight       &#x7C;             $225.00&#x7C;$225.00             &#x7C;<br />
&#x7C;Michael McGovern    &#x7C;B of A Securities   &#x7C;Lowers         &#x7C;Buy              &#x7C;             $220.00&#x7C;$270.00             &#x7C;<br />
&#x7C;Michael Montani     &#x7C;Evercore ISI Group  &#x7C;Lowers         &#x7C;In-Line          &#x7C;             $240.00&#x7C;$250.00             &#x7C;<br />
&#x7C;Rajat Gupta         &#x7C;JP Morgan           &#x7C;Raises         &#x7C;Overweight       &#x7C;             $365.00&#x7C;$350.00             &#x7C;<br />
&#x7C;Chris Pierce        &#x7C;Needham             &#x7C;Maintains      &#x7C;Buy              &#x7C;             $340.00&#x7C;$340.00             &#x7C;<br />
&#x7C;Jeff Lick           &#x7C;Stephens &amp; Co.      &#x7C;Maintains      &#x7C;Overweight       &#x7C;             $300.00&#x7C;$300.00             &#x7C;<br />
&#x7C;Jeff Lick           &#x7C;Stephens &amp; Co.      &#x7C;Maintains      &#x7C;Overweight       &#x7C;             $300.00&#x7C;$300.00             &#x7C;<br />
&#x7C;Ronald Josey        &#x7C;Citigroup           &#x7C;Raises         &#x7C;Buy              &#x7C;             $320.00&#x7C;$277.00             &#x7C;<br />
&#x7C;Michael McGovern    &#x7C;B of A Securities   &#x7C;Raises         &#x7C;Buy              &#x7C;             $270.00&#x7C;$252.00             &#x7C;<br />
&#x7C;Michael Baker       &#x7C;DA Davidson         &#x7C;Raises         &#x7C;Neutral          &#x7C;             $260.00&#x7C;$220.00             &#x7C;<br />
&#x7C;Brad Erickson       &#x7C;RBC Capital         &#x7C;Raises         &#x7C;Outperform       &#x7C;             $320.00&#x7C;$280.00             &#x7C;<br />
&#x7C;Colin Sebastian     &#x7C;Baird               &#x7C;Raises         &#x7C;Neutral          &#x7C;             $250.00&#x7C;$200.00             &#x7C;<br />
&#x7C;Chris Pierce        &#x7C;Needham             &#x7C;Raises         &#x7C;Buy              &#x7C;             $340.00&#x7C;$330.00             &#x7C;<br />
&#x7C;Seth Basham         &#x7C;Wedbush             &#x7C;Maintains      &#x7C;Neutral          &#x7C;             $250.00&#x7C;$250.00             &#x7C;<br />
&#x7C;Jeff Lick           &#x7C;Stephens &amp; Co.      &#x7C;Maintains      &#x7C;Overweight       &#x7C;             $300.00&#x7C;$300.00             &#x7C;<br />
&#x7C;Rajat Gupta         &#x7C;JP Morgan           &#x7C;Raises         &#x7C;Overweight       &#x7C;             $350.00&#x7C;$300.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Carvana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carvana compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Carvana's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Carvana's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CVNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Carvana analyst ratings.</strong></a></p>
<h2>About Carvana</h2>
<p>Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.</p>
<h3>Carvana: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Carvana's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>46.33%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.23%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Carvana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.44%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Carvana's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.0%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Carvana's debt-to-equity ratio surpasses industry norms, standing at <strong>4.8</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CVNA

Assessing Carvana: Insights From 23 Financial Analysts

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Rivian Automotive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RIVN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Rivian Automotive.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 53% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $273,907, and 12 are calls, for a total amount of $729,402.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $22.5 for Rivian Automotive over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Rivian Automotive's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rivian Automotive's whale activity within a strike price range from $10.0 to $22.5 in the last 30 days. </p>
<h3>Rivian Automotive Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745866871_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$7.9</td>
<td>$7.8</td>
<td>$7.9</td>
<td>$20.00</td>
<td>$199.0K</td>
<td>1</td>
<td>255</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$0.97</td>
<td>$0.94</td>
<td>$0.97</td>
<td>$17.50</td>
<td>$194.0K</td>
<td>22.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$1.01</td>
<td>$0.95</td>
<td>$1.01</td>
<td>$20.00</td>
<td>$90.9K</td>
<td>18.9K</td>
<td>1.8K</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$1.01</td>
<td>$0.95</td>
<td>$1.01</td>
<td>$20.00</td>
<td>$90.9K</td>
<td>18.9K</td>
<td>900</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.11</td>
<td>$1.08</td>
<td>$1.08</td>
<td>$20.00</td>
<td>$54.0K</td>
<td>27.8K</td>
<td>694</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rivian Automotive</h3>
<p>Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues primarily from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.</p>
<p>Following our analysis of the options activities associated with Rivian Automotive, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Rivian Automotive</h3>
<ul>
<li>With a trading volume of 21,249,347, the price of RIVN is up by 1.19%, reaching $12.77.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 8 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Rivian Automotive</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $11.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on Rivian Automotive, maintaining a target price of $12.<br />
&#x2A; An analyst from Baird persists with their Neutral rating on Rivian Automotive, maintaining a target price of $14.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Neutral rating for Rivian Automotive, targeting a price of $12.<br />
&#x2A; An analyst from Mizuho has decided to maintain their Neutral rating on Rivian Automotive, which currently sits at a price target of $10.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Underweight rating on Rivian Automotive with a target price of $10. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rivian Automotive options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Comments

Aytu BioPharma

Aytu BioPharma (AYTU) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO